SNY Sanofi

By Joshua Kirby

The European Union's medicines authority has begun a rolling review of French pharmaceutical company Sanofi SA's Covid-19 vaccine candidate, Vidprevtyn, after preliminary study results suggest it could be effective in protecting against the virus.

The European Medicines Agency's human medicines committee, or CHMP, will evaluate data as they become available to see if the benefits of Vidprevtyn outweigh its potential risks, the agency said on Tuesday. The rolling review will continue until enough evidence is available for a formal marketing-authorization application.

The EMA said it can't estimate overall timelines, but an eventual application should take less time than normal in light of the review.

Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby

(END) Dow Jones Newswires

July 20, 2021 11:30 ET (15:30 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.